Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study

Neurologia. 2015 May;30(4):214-22. doi: 10.1016/j.nrl.2013.12.008. Epub 2014 Jan 28.
[Article in English, Spanish]

Abstract

Introduction: Non-adherence to disease-modifying therapies (DMTs) in multiple sclerosis may be associated with reduced efficacy. We assessed compliance, the reasons for non-compliance, treatment satisfaction, and quality of life (QoL) of patients treated with first-line therapies.

Methods: A cross-sectional, multicenter study was conducted that included relapsing multiple sclerosis patients. Compliance in the past month was assessed using Morisky-Green test. Seasonal compliance and reasons for non-compliance were assessed by an ad-hoc questionnaire. Treatment satisfaction and QoL were evaluated by means of TSQM and PRIMUS questionnaires.

Results: A total of 220 patients were evaluated (91% relapsing-remitting); the mean age was 39.1 years, 70% were female, and the average time under treatment was 5.4 years. Subcutaneous interferon (IFN) β-1b was used in 23% of the patients, intramuscular IFN β-1a in 21%, subcutaneous IFN β-1a in 37%, and with glatiramer acetate in 19%. The overall compliance was 75%, with no significant differences related to the therapy, and 81% did not report any seasonal variation. Compliant patients had significantly lower disability scores and time of diagnosis, and greater satisfaction with treatment and its effectiveness. Discomfort and flu-like symptoms were the most frequent reasons for non-compliance. The satisfaction and QoL were associated with less disability and number of therapeutic switches.

Conclusions: The rate of compliance, satisfaction and QoL in multiple sclerosis patients under DMTs is high, especially for those newly diagnosed, less disabled, and with fewer therapeutic switches. Discomfort and flu-like symptoms associated with injected therapies significantly affect adherence.

Keywords: Acetato de glatirámero; Calidad de vida; Compliance; Cumplimiento; Esclerosis múltiple; Glatiramer acetate; Interferon beta; Interferón beta; Multiple sclerosis; Quality of life; Satisfacción; Satisfaction.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Age of Onset
  • Cross-Sectional Studies
  • Female
  • Humans
  • Injections, Subcutaneous
  • Interferon-beta / adverse effects
  • Interferon-beta / therapeutic use*
  • Male
  • Medication Adherence*
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Patient Satisfaction
  • Quality of Life
  • Surveys and Questionnaires

Substances

  • Interferon-beta